S&P 500 and Dow Start the Week With Major Gains Due To ‘Economy Reopening’ Stocks

S&P 500 and Dow Start the Week With Major Gains Due To ‘Economy Reopening’ Stocks
TradeGM Analysis date_range May 5th, 2021

The S&P 500 and Dow had a successful start of the week on Monday due to the U.S. reopening its economy over the past week, as COVID-19 cases decline. Restrictions have been loosening across states; while the mask mandate remains in force all over the country, some states have lifted restrictions on outdoor dining and entertainment facilities and have allowed citizens to move more freely around the country. 

The Highs 

S&P sectors that are economy-sensitive such as energy, manufacturing, and consumer staples, outperformed the usual leaders – tech and communications stocks. 

The biggest gainer was oil giant Baker Hughes that rose by 8%. Retailers Gap and Foot Locker also saw the light at the end of the COVID-19 tunnel with 7.1% and 4.1% gains, respectively. 

“All of those names that are having outsized gain today are as a result of economic reopening optimism, and people getting out of the house spending money on things,” said managing director of equity trading at Wedbush Securities, Michael James. 

Trading volume on U.S. exchanges rose from 9.86 billion to 10.29 billion shares during an average full trading session over the last 20 days. 

“We’ve seen a slight change in the pace of value stocks outperforming growth stocks year-to-date,” said managing director at UBS Private Wealth Management, Rod von Lipsey. 

The Lows 

At the same time, Nasdaq found itself declining, following a few successful past weeks. Tech giants like Amazon and Microsoft declined as investors focused on different sectors. The impact of global news remains imperative on the stock market, particularly during the pandemic. 

The two companies that seemed to most affect the index’s performance was the pharmaceutical company Novavax and, to everyone’s surprise, Tesla. 

Supply Chain Troubles and Delays 

Novavax received some negative news regarding their vaccine against COVID-19, NVX-CoV2373. The company’s production timeline does not coincide with investors’ wishes. Novavax has spent months developing its vaccine and then working on a deal with the European Union to export it for vaccination efforts.  

The company announced that it wouldn’t manage to deliver the 200 million doses agreed on until 2022. Investors were largely disappointed with this announcement, despite the fact that the company announced its plans on starting an expansion of its phase 3 trial to vaccinate those between 12 and 17. Currently, youths under the age of 16 cannot be vaccinated, even under Emergency Use Authorization. The company’s shares dropped by 16% following the announcement. 

Tesla is in a similar boat. While the company had plans to boost production in the coming future and has been focused on expanding its capacity, this has proven to not be easy. The company’s shares fell by over 4%. 

Unfortunately, Tesla’s factory in Berlin announced that it will not be able to open its facilities until mid-July. The plant was meant to assist the company in its plans to expand by 50%. 

Legal disclaimer: The material does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instruments. Ebrókerház Ltd accepts no responsibility for any use that may be made of these comments and for any consequences resulting in it. No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. The information presented does not involve any specific investment objectives, financial situation, and needs of any specific person who may receive it. Past performance does not constitute a reliable indicator of future results and future forecasts do not constitute a reliable indicator of future performance.

Please consider that no news or information shared, nor any content included in any other document available in this website, should be understood in any way, either explicitly or implicitly, directly or indirectly as investment advice, recommendation, or a proposal for an investment strategy related to a financial instrument, as these are made available to you solely for information purposes. The data and information disclosed in the news or in the website, or the analyses attached to trading charts, only reflect the result of a technical analysis done by a professionally independent third party and may change without any prior notice.

The clients of eBrókerház Befektetési Szolgáltató Zrt. open orders through the Trade GM Trader Online Trading Platform, the orders will be forwarded to an execution venue defined in our Execution Policy. Trade GM Trader Online Platform is operated by eBrókerház Szolgáltató zrt, which is authorized and regulated by the Hungarian National Bank under the licence numbers III/73.059/2000. and III/73.059-4/2002.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.42% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. The materials contained on this page are for advertising and marketing purposes only and should not in any way be construed, either explicitly or implicitly, directly or indirectly. as investment advice, recommendation or suggestion of an investment strategy with respect to a financial instrument, in any manner whatsoever. You should make sure that you have sufficient time to manage your investments on an active basis. CDF are derivative financial instruments, which price is derived from the price of the underlying asset or contract to which the CFD refers (for example currencies, commodities, indices, equity, etc.). Derivative financial instruments and related markets can be highly volatile. The prices of CFDs and underlying instrument may fluctuate rapidly over wide ranges and may reflect unforeseeable events or changes in conditions, none of which can be controlled by the client or eBrókerház Befektetési Szolgáltató Zrt. Prices quoted or information may vary and change depending on market conditions. When investing in Company’s Products denominated in a currency other than that of the state in which you reside, the return may increase or decrease as a result of currency fluctuations. Any indication of past performance or simulated past performance included in an advertisement is not a reliable indicator of future results. All names, pictures and personal details of people depicted as traders in advertisements concerning past performance are included for presentation purposes only, and are not the actual traders who have made the transaction detailed in the advertisement (actual details are kept for privacy purposes). All opinions expressed by traders are not actual testimonials but rather are depictive of the actual past performance and trading experience. Any trades depicted are selected from past real successful trades and are not reliable indicator of all customers past or future trades.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.42% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. X